NeuroPointDX is the neurological disorders division of Stemina Biomarker Discovery that uses the same metabolomics platform that Stemina employs for its toxicology assays.
Through NeuroPointDX, we have developed a first-generation test, the NeuroPointDX Autism Spectrum (NPDX ASD) Test, to assist with the diagnosis of autism spectrum disorder (ASD). This blood test is based on what we learned in our 1,100-patient clinical study, the Children’s Autism Metabolome Project (CAMP).
The NPDX ASD test has been NeuroPointDX’s primary focus. We continue to look for ways to identify more children with ASD and to advise treatment that addresses their specific needs.
NeuroPointDX’s work is also relevant to many other types of neurological disorders that are notoriously hard to diagnose and treat, including schizophrenia, depression, and anxiety.